Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19095368 | 0.86 | MAPT (0.47) | CACNA1GKCNA5MEN1KMT2ASLC6A2 | |
| SCHEMBL4778842 | 0.84 | HSP90AB1 (0.40) | CACNA1GKCNA5MEN1KMT2ASLC6A2 | |
| SCHEMBL4887895 | 0.83 | CHRM4 (0.40) | CACNA1GKCNA5MEN1KMT2ASLC6A2 | |
| SCHEMBL17432438 | 0.79 | PPARD (0.49) | CACNA1GKCNA5MEN1KMT2AALDH1A1 | |
| SCHEMBL19538665 | 0.78 | TSHR (0.68) | KCNA5KMT2AALDH1A1TSHRPPARD | |
| SCHEMBL19095372 | 0.77 | ALDH1A1 (0.43) | CACNA1GKCNA5MEN1KMT2ASLC6A2 | |
| SCHEMBL2093175 | 0.77 | ALDH1A1 (0.50) | KCNA5MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL22963896 | 0.76 | HRH3 (0.58) | KCNA5TSHRPPARDPPARACHRM4 | |
| SCHEMBL5536931 | 0.76 | KCNA5 (0.53) | KCNA5KMT2AALDH1A1CHRM4MAPT | |
| SCHEMBL30022640 | 0.75 | KCNA5 (0.51) | KCNA5MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| EP-1984369-A2 | NITROIMIDAZOLE COMPOUNDS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | CACNA1G 3640/4885KCNA5 2226/4885ADRA2A 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.